Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Acute lymphoblastic leukemia (ALL) Clinical Trials

Protocol Number Title
2001LS058
MT2001-10 Allogeneic Bone Marrow Transplant Using Less Intensive Therapy
2005LS036
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
2005LS043
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
2007NT102
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples.
2009NTLS130
Hematologic Malignancy Tissue Bank Formerly: "Leukemia, Lymphoma and MDS Tissue Bank" Formerly: "Leukemia and MDS Tissue Bank" & "Pediatric Leukemia Tissue Bank"
2010NTCG113
COG AALL08B1 - Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
2011CG161
COG AALL1131 - A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations. Additional Title: Per Case Reimbursement NIH National Clinical Trials Network (NCTN) BIQSFP Grant U10CA180886-02S7 Add: AALL1131 Osteonecrosis Sub-study Per Case Reimbursement
2012CG099
COG ACCL1033 - A Comprehensive Approach to Improving Medication Compliance in Pediatric ALL
2014CG089
COG AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
2014CG123
MT2016-21 : COG AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) "AALL1331 - Amgen, Inc."
2014LS093
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
2015IS090
HM2015-22 A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
2015IS101
HM2015-26 A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
2015IS158
HM2015-40: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician?s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2016LS107
MT2016-17 Adoptive Transfer of T Regulatory Cell with IL-2 Support for Suppression of Acute Graft-vs- Host-Disease after a Double Umbilical Cord Blood Transplant for Hematologic Malignancies
2016NTLS038
HM2016-30R Immune Monitoring During ASP2215 Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)

17 trials displayed